Post-marketing surveillance system for drugs in pregnancy—15 years experience of ENTIS
- 31 October 2005
- journal article
- review article
- Published by Elsevier BV in Reproductive Toxicology
- Vol. 20 (3), 331-343
- https://doi.org/10.1016/j.reprotox.2005.03.012
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Communicating risks during pregnancy: A workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugsBirth Defects Research Part A: Clinical and Molecular Teratology, 2004
- Classification of drugs for teratogenic risk: An anachronistic way of counseling: A reply to Merlob and StahlBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Monitoring leflunomide (Arava) as a new potential teratogenTeratology, 2002
- Long term health and neurodevelopment in children exposed to antiepileptic drugs before birthJournal of Medical Genetics, 2002
- Adverse effects of prenatal methimazole exposureTeratology, 2001
- Selection bias in Teratology Information Service pregnancy outcome studiesTeratology, 2001
- The Teratogenicity of Anticonvulsant DrugsThe New England Journal of Medicine, 2001
- Problems of using data from teratology information services (TIS) to identify putative teratogensTeratology, 1999
- Teratogenic Agent Information Centre: Fifteen years of counseling and pregnancy follow-upTeratology, 1992
- Experience of two teratology information services in EuropeTeratology, 1990